Thomas F Patterson, M.D.

• Professional Background

  Education

  • 1983 - MD - Medicine - McGovern Medical School
  • 1979 - BA - Chemistry (Magna Cum Laude) - Baylor University
  • Residency - Internal Medicine - Yale-New Haven Hospital
  • Postdoctoral Fellowship - Infectious Diseases - Yale University School of Medicine
  • Postdoctoral Fellowship - Summer Course in Medical Mycology - Duke University
  • Internship - Internal Medicine - Vanderbilt University Hospital
  • Residency - Internal Medicine - Vanderbilt University Hospital

  Appointments

  • 2/2017 - Vice-Chair for Faculty Development and Other - University of Texas Health Science Center at San Antonio, Medicine, San Antonio
  • 9/2008 - Division Chief, Infectious Diseases - University of Texas Health Science Center at San Antonio, Medicine, San Antonio
  • 7/2004 - Director - San Antonio Center for Medical Mycology
  • 9/2000 - Professor - University of Texas Health Science Center at San Antonio, Medicine, San Antonio
  • 1/1993 - Director, In-Patient AIDS Service; Attending Physician; Consultant in Infectious Diseases - University Hospital, Medicine, San Antonio
  • 1/1993 - Attending Physician; Consultant in Infectious Diseases - South Texas Veterans Healthcare System, Audie L. Murphy Division, Medicine, San Antonio

• Instruction & Training

  • 1/2016 - Present, Individual Instruction, UTHSCSA
  • 1/2016 - Present, Post-Doctoral Student Supervision, UTHSCSA
  • 4/2009 - Present, Medical Mycology and Advanced Medical Mycology, University of Texas at San Antonio
  • 1/2007 - Present, High School/Junior High School Student Supervision
  • 1/2006 - Present, Veritas Group Leader, UTHSCSA
  • 9/2005 - Present, Post-Doctoral Student Supervision, UTHSCSA
  • 1/2005 - Present, Individual Instruction, UTHSCSA
  • 9/2004 - Present, Tuesday Infectious Diseases Conference, ALMVAH
  • 7/2004 - Present, Post-Doctoral Student Supervision, UTHSCSA
  • 8/2001 - Present, Medicine Residents Didactic Series, UTHSCSA
  • 8/2000 - Present, HIV Medicine Team 6/Infectious Diseases Didactic Series, UTHSCSA
  • 1/1993 - Present, HIV Medicine Team 6/Infectious Diseases Didactic Series, UTHSCSA
  • 1/1993 - Present, ID Didactic Lecture Series, Multiple (VA, UHS, UT Health San Antonio)
  • 1/1993 - Present, Medical Block Course Registratio, The University of Texas Health Science Center
  • 1/1993 - Present, Clin Infectious Disease, The University of Texas Health Science Center

• Research & Grants

  Research profile

  Grants

  Federal

  Funding Agency NIH/NIAID Title Pre-clinical Models of Infectious Diseases Status Active Period 7/2017 - 7/2024 Role Principal Investigator Grant Detail HHSN272201000039I/HHSN27200001 - Base award for NIH contracts for pre-clinical models of infectious diseases Funding Agency NIH-NIAID Title Development of a New System for Scaled Up Culture and Propagation of Pneumocystis (Task A22) Status Active Period 8/2016 - 7/2018 Role Principal Investigator Grant Detail HHSN272201100018I/HHSN27200003/HHSN27200004/Task A22
  NIH contract to establish cultivation system for Pneumocystis Funding Agency NIH/NIAID Title In Vitro Assessment for Antimicrobial Activity Part A Task Order Solicitation - Task A29 Invitro Screening for Antibacterial Activity Status Active Period 6/2011 - 5/2018 Role Principal Investigator Grant Detail HHSN272201100018I/HHSN27200005/HHSN27200013
  Task A28: 5/16/17-5/15/18
  Task A21 $218,716 Funding Agency NIH/NIAID Title In Vitro Assessment for Antimicrobial Activity Part A Task Order Solicitation - Task A16/17 In Vitro Screening for Antifungal and Antibacterial Activity Status Active Period 6/2011 - 5/2018 Role Principal Investigator Grant Detail HHSN272201100018I/HHSN27200005/HHSN27200006 Funding Agency NIH/NIAID Title In Vitro Assessment for Antimicrobial Activity Part A Task Order Solicitation - Task A28 In Vitro Screening for Antifungal Activity Status Active Period 6/2011 - 5/2018 Role Principal Investigator Grant Detail HHSN272201100018I/HHSN27200005/HHSN27200012 Funding Agency NIH/NIAID Title In Vitro Assessment for Antimicrobial Activity Part A Task Order Solicitation - Task A10/12 In Vitro Screening for Antifungal and Antibacterial Activity Status Active Period 6/2011 - 5/2018 Role Principal Investigator Grant Detail HHSN272201100018I/HHSN27200005/HHSN27200006 Funding Agency NIH/NIAID Title In Vitro Assessment for Antimicrobial Activity Par A Task Order Solicitation - Task A06/A09, In Vitro Screening for Antifungal and Antibacterial Activity Status Active Period 6/2011 - 5/2018 Role Principal Investigator Grant Detail HHSN272201100018I/HHSN27200003/HHSN27200004 Funding Agency NIH-NIAID Title In Vitro Testing for Antimicrobial Resistant-related Antibacterial Activity - CARB-X - Task A29 Status Active Period 5/2017 - 5/2018 Role Principal Investigator Grant Detail In vitro contract to assess novel antimicrobial activity against drug resistant pathogens Funding Agency NIH/NIAID Title In Vitro Assessment for Antimicrobial Activity Part A Task Order Solicitation - Task A26 In Vitro Screening for Antifungal Activity Status Active Period 6/2011 - 5/2018 Role Principal Investigator Grant Detail HHSN272201100018I?HHSN27200005/HHSN27200011 Funding Agency NIH-NIAID Title Gender Differences in Murine Models of Fungal Infections - Aspergillosis (Task A97) Status Active Period 7/2016 - 3/2018 Role Principal Investigator Grant Detail HHSN272201000038I/HHSN27200007/Task A97
  NIH contract to evaluate sex differences in animal models of Aspergillosis Funding Agency NIH-NIAID Title Gender Differences in Murine Models of Fungal Infections - Mucormycosis (Task 102) Status Active Period 8/2016 - 2/2018 Role Principal Investigator Grant Detail HHSN272201000038I/HHSN27200008/Task A102
  NIH contract to establish sex differences in animal models of Mucormycosis Funding Agency NIH-NIAID Title In Vitro Screening for Antifungal Activity (Task A28) Status Active Period 3/2017 - 2/2018 Role Principal Investigator Grant Detail NIH/NIAID HHSN272201000018I/HHSN27200012
  In vitro contract to assess novel antifungal activity against resistant pathogens Funding Agency NIH-NIAID Title Antifungal in vivo Efficacy Testing - Coccidioides Status Active Period 8/2016 - 11/2017 Role Principal Investigator Grant Detail HHSN272201000038I/HHSN27200006/Task A98
  NIH contract to evaluate antifungal agents in animal models of Coccidioidomycosis Funding Agency NIH-NIAID Title Therapeutics Testing in Murine Model of Aspergillosis and Candidiasis (A107) Status Active Period 3/2017 - 11/2017 Role Principal Investigator Grant Detail HHSN272201000038I/HHSN27200009/Task A107
  Contract to assess antifungal activity against candida and aspergillus Funding Agency NIH-NIAID Title In Vitro Screening for Bacterial Activity (Task A26) Status Complete Period 7/2016 - 7/2017 Role Principal Investigator Grant Detail Funding Agency NIH/NIAID Title Staphylococcus aureus small animal model proof-of-concept testing of therapeutics and vaccine for antimicrobial resistance. Status Active Period 9/2011 - 3/2017 Role Principal Investigator Grant Detail HHSN272201000038I/HHSN27200003/Task A24

  Small Animal Model Proof-of-Concept Testing of Therapeutics and Vaccine for Antimicrobial Resistance.
  This contract supports studies to utilize an established model of murine Staphylococcus aureus bacteremia to evaluate new therapeutic options and vaccines.

   

  Private

  Funding Agency Fujisawa Healthcare, Inc. Title A Phase 3, Randomized, Dobule-Blind, Comparative Study of Micafungin (FK463) Versus Caspofungin as Antifungal Treatment in Patients with Invasive Candidiasis or Candidemia.(03-0-192) Status Active Period 10/2004 - Present Role Principal Investigator Grant Detail The objective of the study is to determine the efficacy and safety of two dose levels of intravenous micafungin (100 mg/day and 150 mg/day) verus intravenous caspofungin in the treatment of patients with confirmed invasive candidiasis or candidemia.

• Publications

  Abstract

  Patterson J. Wiederhold NP, McElmeel M. Patterson TF. In vitro Susceptibility Testing of Essential Oils against Gram-positive and Gram-negative Clinical Isolates, including Carbapenem-resistant Enterobacteriaceae (CRE); 2017 Oct. (Poster Presentation at IDWeek 2017). Gebremariam T, Alkhazraji S. Alqarhi A, Wiederhold NP, Shaw K, Patterson TF, Filler SG, Ibrahim AS. APX001A Protects Immunosuppressed Mice from Rhizopus delemar Infection; 2017 Oct. (Poster Presentation at IDWeek 2017). Schwartz IS, Wiederhold NP, Patterson TF, Sigler L. Blastomyces helicus, a Cause of Pulmonary and Disseminated Blastomycosis in Immunocompromised Persons and Companion Animals in Western Canada and United States; 2017 Oct. (Poster Presentation at IDWeek 2017). Wiederhold NP, Jorgensen JH, McElmeel ML, Najvar LK, Catano G, Patterson TF. In vitro Activity of Fosfomycin Alone and Combined with Cefepime and Meropenem against Carbapenemase-Producing Gram-Negative Bacteria; 2017 Oct. (Poster Presentation at IDWeek 2017). Wiederhold NP, Najvar LK, Jaramillo R, Olivo M, Catano G, Sullivan SM, Hopkins AM, Smith LR, Patterson TF. The Novel Antifungal VL-2397 Demonstrates Efficacy in an In vivo Model of Invasive Candidiasis Caused by Wild-Type and Multi-Drug Resistant Candida glabrata; 2017 Jun. (Poster Presentation at ASM Microbe 2017). Wiederhold NP, Fothergill AW, Patterson TF, Sutton DA. Review of Aspergillus spp. Collected from Brain, Cerebral Spinal Fluid, Vitreous Fluid, and Corneas in the United States; 2016 Jan. (Poster Presentation at the 7th Advances Against Aspergillosis Meeting). 285. Cadena Zulaga J, Goritsas J, Lopez Vasquez M, Patterson T, Frei C. Candida Endophthalmitis/Chorioretinitis: Incidence and Clinical Characteristics in a University Hospital; 2016 Jan. (Poster Presentation at 2017 IDWeek). Kapoor R, Wiederhold N, Najvar LK, Patterson TF, Chang W. A Rapid and Sensitive (1?3)-?-D-Glucan Microfluidic Assay for Early Detection of Invasive Aspergillosis Infections in a Murine Model; 2016 Jan. (Poster Presentation at ASM Microbe 2016). Wiederhold NP, Jorgensen JH, McElmeel ML, Najvar LK, Catano OG, Patterson TF. An NIH/NIAID Initiative for the In vitro Assessment of Novel Antibacterial Compounds; 2016 Jan. (Poster Presentation at the ASM Conference on Antibacterial Development). Wiederhold NP, Dorsey S, Patterson TF. Clinically Achievable Concentrations of Posconazole Before and After the Availability of the Delayed Release Tablet and Intravenous Formulations; 2016 Jan. (Poster Presentation at the XIX Immuncompromised Host Society Symposium, XIV INFOCUS Meeting). Najvar LK, Galgiani JN, Nix DE, Bocanegra R, Patterson TF, Wiederhold NP. Combination Therapy with VFS1 and Caspofungin Improves Survival in Experimental Invasive Aspergillosis (IPA); 2015 Jan. (Oral Presentation at the 55th Interscience Conference on Antimicrobial Agents and Chemotherapy). Gebremariam T, Wiederhold NP, Fothergill AW, Patterson T, Filler S, Ibrahim AS. VT-1161 Protects Immunosuppressed Mice from Rhizopus oryzae Infection; 2015 Jan. (ePoster Oral Presentation at the 25th European Congress of Clinical Microbiology and Infectious Diseases). Wiederhold NP, Jorgensen JH, Boakes S, Collins MS, McElmeel M, Cushion MT, Patterson TF. Antibacterial Activity of Novel Polymyxin B Derivatives Against Gram-negative Bacteria and Initial Toxicity Assessment; 2015 Jan. (Poster Presentation at the 55th Interscience Conference on Antimicrobial Agents and Chemotherapy). Wiederhold NP, Najvar LK, Alimardanov A, Cradock J, Xu X, Behnke M, Ottinger EA, Hoekstra WJ, Garvey EP, Brand SR, Schotzinger RJ, Bocanegra R, Kirkpatrick WR, Patterson TF. The Novel Fungal Cyp51 Inhibitor VT-1129 Demonstrates Potent In vivo Activity against Cryptococcal Meningitis with a Loading/Maintenance Dosing Regimen; 2015 Jan. (Poster Presentation at the 25th European Congress of Clinical Microbiology and Infectious Diseases). Wiederhold NP, Ibrahim AS, Warn P, Najvar LK, Wickes BL, Kadosh D, Kirkpatrick WR, Filler S, Patterson TF. A U.S. National Institutes of Health Resource for the In Vivo Assessment of Novel Antifungal Compounds and Diagnostic Assays; 2015 Jan. (Poster Presentation at the 19th International Congress of the International Society of Human and Animal Mycoses). Bocanegra R, Wiederhold NP, Najvar LK, Fothergill AW, McCarthy DI, Kirkpatrick WR, Fukuda Y, Mitsuyama J, Patterson TF. The Novel Arylamidine T-2307 Demonstrates In Vitro and In Vivo Activity Against Echinocandin Resistant Candida glabrata; 2015 Jan. (Oral Presentation at the 19th International Congress of the International Society of Human and Animal Mycoses). Najvar LK, Wiederhold NP, Alimardanov A, Cradock J, Xu X, Behnke M, Ottinger EA, Hoekstra WJ, Garvey EP, Brand SR, Schotzinger RJ, Bocanegra R, Kirkpatrick WR, Patterson TF. VT-1129 Demonstrates Potent In Vivo Activity in Mice against Cryptococcal Meningitis when Administered Alone or when Combined with Amphotericin B; 2015 Jan. (Poster Presentation at the 19th International Congress of the International Society of Human and Animal Mycoses). Gebremariam T, Wiederhold NP, Garvey EP, Hoekstra WJ, Schotzinger RJ, Patterson TF, Filler SG, Ibrahim AS. Prophylactic Treatment of Pulmonary Mucormycosis with VT-1161 Using Immunosuppressed Mice; 2015 Jan. (Oral Presentation at the 55th Interscience Conference on Antimicrobial Agents and Chemotherapy). Musumechi R, Wiederhold NP, Jorgensen JH, Patterson TF, Bulbarelli A, Sancini G, Pace A, Palumbo Piccionello A, Fortuna CG, Cocuzza CE. Preclinical Development of MiBIECT, a New Oxadiazolyl-Oxazolidinone Compound Active Against Gram-positive Cocci; 2015 Jan. (Poster Presentation at the 55th Interscience Conference on Antimicrobial Agents and Chemotherapy). Proniuk S, Wiederhold NP, Patterson TF, Cushion MT, Krysan DJ, Green J, Koselny K, Zukiwski A. AR-12, Lead Compound of a Potential New Class of Antifungal Agents; 2015 Jan. (Poster Presentation at the 55th Interscience Conference on Antimicrobial Agents and Chemotherapy).

  Book Chapter

  Sutton, DA, Patterson TF. Malassezia species (chapter 248). In: Long SS, Pickering LK, Prober CG (Eds). Principles and Practice of Pediatric Infectious Diseases 5th Ed. 2017. Thompson GR III, Patterson TF. Cryptococcus species (chapter 249). In: Long SS, Prober CG, Fischer M (Eds). Principles and Practice of Pediatric Infectious Diseases 5th Ed. 2017. Patterson TF, Sutton, DA. Agents of mucormycosis (zygomycosis) (chapter 247). In: Long SS, Prober CG, Fischer M (Eds). Principles and Practice of Pediatric Infectious Diseases 5th Ed. 2017. Patterson TF, Sutton, DA. Agents of hyalohyphomycosis and phaeohyphomycosis (chapter 246). In: Long SS, Prober CG, Fischer M (Eds). Principles and Practice of Pediatric Infectious Diseases 5th Ed. 2017. Patterson TF, Sutton, DA. Classification of fungi (chapter 243). In: Long SS, Prober CG, Fischer M (Eds). Principles and Practice of Pediatric Infectious Diseases 5th Ed. New York: Elsevier; 2017. Lopez-Ribot JL, Patterson TF. Fungal drug resistance: Azoles ( Chapter 27). In: Mayers DL, Sobel JD, Kaye K, Ouellette M, eds. Antimicrobial Drug Resistance. 2017. Patterson TF, Sutton, DA. Sporothrix schenckii (sporotrichosis) (chapter 249). In: Long SS, Prober CG, Fischer M (Eds). Principles and Practice of Pediatric Infectious Diseases 5th Ed. 2017. Thompson GR III, Patterson TF. Antifungal Agents (Chapter 15). In: Maschmeyer G, Rolston KVI (Eds). Infections in Hematology. 2015. p. 259-272. Patterson TF. Aspergillus species (chapter 259). In: Dolin R, Bennett JE, Blaser MJ, eds. Mandell, Douglas, and Bennett?s Principles and Practice of Infectious Diseases, 8th edition. 2015. p. 2895-2908. Wiederhold NP, Patterson TF. Antifungal Therapy (Chapter 207). In: Schlossberg D, ed. Clinical Infectious Disease. 2015. p. 1344-1352. Thompson GR, III, Patterson TF. Antifungal Drugs: Mechanisms of Action, Drug Resistance, Susceptibility Testing, and Assays of Activity in Biologic Fluids (chapter 6). In: Amsterdam D (ed). Antibiotics in Laboratory Medicine 6th ed. 2015.

  Journal Article

  Papanastassiou AM, Hajjar, J, Restrepo, A, Javeri HA, Wiederhold NP, Patterson TF. Multiple Brain Abscesses Caused by Trichosporon inkin in a Patient with X-Linked Chronic Granulomatous Disease (CGD) Successfully Treated with Antifungal Therapy Journal of Clinical Immunology 2017 Jul;. Gebremariam T, Alkhazraji S, Lin L, Wiederhold NP, Garvey EP, Hoekstra WJ, Schotzinger RJ, Patterson TF, Filler SG, Ibrahim AS. Prophylactic Treatment with VT-1161 Protects Immunosuppressed Mice from Rhizopus arrhizus var. arrhizus Infection Antimicrob Agents Chemother 2017 Jun;. Wiederhold NP, Patterson TF, Srinivasan A, Chaturvedi AK, Fothergill AW, Wormley FL, Ramasubramanian AK, Lopez-Ribot JL. Repurposing Auranofin as an Antifungal: In Vitro Activity Against a Variety of Medically Important Fungi Virulence 2017 Feb;8(2):138-142. Koselny K, Green J, DiDone L, Halterman JP, Fothergill AW, Wiederhold NP, Patterson TF. The Celecoxib Derivative AR-12 Has Broad-Spectrum Antifungal Activity In Vitro and Improves the Activity In Vitro and Improves the Activity of Fluconazole in a Murine Model of Cryptococcosis Antimicrob Agents Chemother 2016 Nov;60(12):7115-7127. Maincent J, Najvar LK, Kirkpatrick WR, Huang S, Patterson TF, Wiederhold NP, Peters JI, Williams RO. Modified Release Itraconazole Amorphous Solid Dispersion to Treat Aspergillus fumigatus: Importance of Animal Model Selection Drug Dev Ind Pharm 2016 Sep;:1-35. Patterson TF, Thompson GR 3rd, Denning DW, Fishman JA, Hadley S, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Nguyen MH, Segal BH, Steinbach WJ, Stevens DA, Walsh TJ, Wingard JR, Young JH, Bennett JE. Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America Clin Infect Dis 2016 Aug;63(4):e1-e60. Wiederhold NP, Kovanda L, Najvar LK, Bocanegra R, Olivo M, Kirkpatrick WR, Patterson TF. Isavuconazole is Effective for the Treatment of Experimental Cryptococcal Meningitis Antimicrob Agents Chemother 2016 Aug;60:5600-5603. Patterson TF, Thompson GR 3rd, Denning DW, Fishman JA, Hadley S, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Nguyen MH, Segal BH, Steinbach WJ, Stevens DA, Walsh TJ, Wingard JR, Young JA, Bennett JE. Executive Summary: Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America Clin Infect Dis 2016 Aug;63(4):433-442. White PL, Wiederhold NP, Loeffler J, Najvar LK, Melchers W, Herrera M, Bretagne S, Wickes B, Kirkpatrick WR, Barnes RA, Donnelly JP, Patterson TF. Comparison of Nonculture Blood-Based Tests for Diagnosing Invasive Aspergillosis in an Animal Model J Clin Microbiol 2016 Apr;54(4):960-6. Lockhart SR, Fothergill AW, Iqbal N, Bolden CB, Grossman NT, Garvey EP, Brand SR, Hoekstra WJ, Schotzinger RJ, Ottinger E, Patterson TF. The Investigational Fungal Cyp51 Inhibitor VT-1129 Demonstrates Potent In Vitro Activity Against Cryptococcus Neoformans and Cryptococcus Gattii Antimicrob Agents Chemother 2016 Mar;60(4):2528-2531. Bocanegra R, Wiederhold NP, Najvar LK, Fothergill AW, McCarthy DI, Kirkpatrick WR, Fukuda Y, Mitsuyama J, Patterson TF. The Novel Arylamidine T-2307 Demonstrates In Vitro and In Vivo Activity Against Echinocandin-Resistant Candida Glabrata J Antimicrob Chemother 2016 Mar;71(3):692-695. Cadena J, Thompson GR, Patterson TF, Cadena Zuluaga JA. Invasive Aspergillosis: Current Strategies for Diagnosis and Management Infect Dis Clin North Am 2016 Mar;30(1):125-142. Maertens JA, Raad II, Marr KA, Patterson TF, Kontoyiannis DP, Cornely OA, Bow EJ, Rahav G, Neofytos D, Aoun M, Baddley JW, Giladi M, Heinz WJ, Herbrecht R, Hope W, Karthaus M, Lee DG, Lortholary O, Morrison VA, Oren I, Selleslag D, Shoham S, Thompson GR 3rd, Lee M, Maher RM, Schmitt-Hoffmann AH, Zeiher B, Ullmann AJ. Isavuconazole Versus Voriconazole for Primary Treatment of Invasive Mould Disease Caused by Aspergillus and Other Filamentous Fungi(SECURE): A Phase 3, Randomised, Controlled, Non-Inferiority Trial Lancet 2016 Feb;387(10020):760-769. Kadosh, D
  Najvar, LK
  Bocanegra, R
  Olivo, M
  Kirkpatrick, WR
  Wiederhold, N
  Patterson, T. Effect of antifungal treatment in a diet-based murine model of disseminated candidiasis acquired via the gastrointestinal tract Antimicrob Agents Chemother 2016 Jan;60:6703-6708. Reedy J, Negoro P, Feliu M, Lord A, Khan N, Lukason D, Wiederhold N, Tam J, Mansour M, Patterson T, Vyas J. The Carbohydrate Lectin Receptor, Dectin-1, Mediates Immune Response to Exserohilum rostratum Infect Immun 2016 Jan;83:e00903-16. Wiederhold NP, Patterson TF. What's new in antifungals: an update on the in-vitro activity and in-vivo efficacy of new and investigational antifungal agents Curr Opin Infect Dis 2015 Dec;28(6):539-545. Wiederhold NP, Patterson TF. What`s New in Antifungals: An Update on the In-Vitro Activity and In-Vivo Efficacy of New and Investigational Antifungal Agents Curr Opin Infec Dis 2015 Dec;28(6):539-545. Gebremariam T, Wiederhold NP, Fothergill AW, Garvey EP, Hoekstra WJ, Schotzinger RJ, Patterson TF, Filler SG, Ibrahim AS. VT-1161 Protects Immunosuppressed Mice from Rhizopus Arrhizus Var. Arrhizus Infection Antimicrob Agents Chemother 2015 Dec;59(12):7815-7817. Wiederhold NP, Patterson TF. Emergence of Azole Resistance in Aspergillus Semin Respir Crit Care Med 2015 Oct;36(5):673-680. White PL, Wingard JR, Bretagne S, Loffler J, Patterson TF, Slavin MA, Barnes RA, Pappas PG, Donnelly JP. Aspergillus Polymerase Chain Reaction: Systematic Review of Evidence for Clincal Use in Comparison with Antigen Testing Clin Infect Dis 2015 Oct;61(8):1293-1303. Wiederhold NP, Patterson TF. Emergence of Azole Resistance in Aspergillus Semin Respir Crit Care Med 2015 Oct;36(5):673-680. McCarty TP, Baddley JW, Walsh TJ, Alexander BD, Kontoyiannis DP, Perl TM, Walker R, Patterson TF, Schuster MG, Lyon GM, Wingard JR, Andes DR, Park BJ, Brandt ME, Pappas PG. Phaeohyphomycosis in Transplant Recipients: Results from the Transplant Associated Infection Surveillance Network (TRANSNET) Med Mycol 2015 Jun;53(5):440-446. Herbrecht R, Patterson TF, Slavin MA, Marchetti O, Maertens J, Johnson EM, Schlamm HT, Donnelly JP, Pappas PG. Application of the 2008 Definitions for Invasive Fungal Diseases to the Trial Comparing Voriconazole versus Amphotericin B for Therapy of Invasive Aspergillosis: A Collaborative Study of the Mycoses Study Group (MSG 05) and the European Organization for Clin Infect Dis 2015 Mar;60(5):713-720. Wiederhold NP, Najvar LK, Fothergill AW, Bocanegra R, Olivo M, McCarthy DI, Kirkpatrick WR, Fukuda Y, Mitsuyama J, Patterson TF. The Novel Arylamidine T-2307 Maintains In-Vitro and In-Vivo Activity Against Echinocandrin-Resistant Candida Albicans Antimicrob Agents 2015 Feb;59(2):1341-1343. Wiederhold NP, Najvar LK, Fothergill AW, McCarthy DI, Bocanegra R, Olivo M, Kirkpatrick WR, Everson MP, Duncanson FP, Patterson TF. The Investigational Agent E1210 is Effective in Treatment of Experimental Invasive Candidiasis Caused by Resistant Candida Albicans Antimicrob Agents Chemother 2015 Jan;59(1):690-692. Wiederhold NP
  Najvar LK
  Matsumoto S
  Bocanegra RA
  Herrera ML
  Wickes BL
  Kirkpatrick WR
  Patterson TF. Efficacy of the Investigational Echinocandin ASP9726 in a Guinea Pig Model of Invasive Pulmonary Aspergillosis Antimicrob Agents Chemother 2015 Jan;59(5):2875-2881. Kontoyiannis DP, Patterson TF. Diagnosis and Treatment of Invasive Fungal Infections in the Cancer Patient: Recent Progress and Ongoing Questions Clin Infec Dis 2014 Nov;59:S356-S359. Maschmeyer G, Patterson TF. Our 2014 Approach to Breakthrough Invasive Fungal Infections Mycoses 2014 Nov;57(11):645-651. Cadena Zuluaga JA, Thompson GR, Ho TT, Medina EA, Hughes DW, Patterson TF. Immune reconstitution inflammatory syndrome after cessation of the tumor necrosis factor alpha blocker adalimumab in cryptococcal pneumonia Diagn Microbiol Infec Dis 2009 Jul;64(3):327-330.

• Clinical

  Board Certifications

  • American Board of Internal Medicine/Infectious Disease
  • American Board of Internal Medicine